Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20
Piper Sandler analyst David Amsellem maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and lowers the price target from $21 to $20.
Stocks · News reference
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Monday. The Dow traded up 0.44% to 52,105.66 while the NASDAQ rose 1.33% to 25,634.54. The S&P 500 also
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Piper Sandler analyst David Amsellem maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and lowers the price target from $21 to $20.
Wells Fargo analyst Benjamin Burnett maintains Amphastar Pharma (NASDAQ:AMPH) with a Equal-Weight and raises the price target from $19 to $20.
Amphastar Pharma (NASDAQ:AMPH) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.62 by 46.77 percent. This is a 7.06 percent increase over earnings of $0.85 per share from
Comcast maintains higher absolute revenue but Disney demonstrates stronger growth momentum. Comcast's revenue has contracted modestly due to business divestitures, while Disney shows consistent upward trajectory with 7% year-over-year growth in Q2 2026, driven by strong theme park performance. The revenue gap between the two media giants is narrowing, signaling a structural shift in competitive dynamics.
AMD crossed $1 trillion and Meta's Muse rattled subscription stocks. Meanwhile, Treasury yields hit 2007 highs.
Analysts downgraded Nike, Comcast, Restaurant Brands.